This opportunity funds preclinical and patient-based studies to understand how incretin mimetics, including GLP-1 and GIP-1 agents, affect cancer risk. The focus is on mechanistic insights rather than short-term effects like weight loss or diabetes, addressing potential increased or decreased risks of obesity-related cancers.
Eligible applicants include a wide range of U.S.-based entities such as independent school districts, nonprofits, state and local governments, for-profit organizations, tribal governments, and institutions of higher education. Specific eligibility details should be confirmed in the official announce
